» Authors » David Leiman

David Leiman

Explore the profile of David Leiman including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 102
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sessler D, Bao X, Leiman D, Song J, Chittenden J, Voelkner A, et al.
J Clin Pharmacol . 2024 Nov; PMID: 39520051
This trial assessed the pharmacokinetics, pharmacodynamics, and safety of liposomal bupivacaine given via ultrasound-guided popliteal sciatic nerve block with or without immediate-release bupivacaine hydrochloride in adults having bunionectomies. Forty-five adults...
2.
Shafer S, Teichman S, Gottlieb I, Singla N, Minkowitz H, Leiman D, et al.
Anesthesiology . 2024 Apr; 141(2):250-261. PMID: 38662910
Background: Nonopioid management of postsurgical pain remains a major unmet need. Few studies have evaluated transient receptor potential vanilloid subfamily member 1 agonists for analgesia after surgery. This study examines...
3.
Beaton A, Solanki D, Salazar H, Folkerth S, Singla N, Minkowitz H, et al.
Reg Anesth Pain Med . 2023 Apr; 48(12):601-607. PMID: 37076252
Introduction: Surgical site infiltration with bupivacaine hydrochloride (HCl) is a standard element of postoperative analgesia for soft tissue surgeries, but results in short-lived analgesia. A novel bupivacaine implant, XARACOLL (bupivacaine...
4.
Leiman D, Jove M, Spahn G, Palmer P
J Pain Res . 2021 Apr; 14:805-813. PMID: 33790642
Objective: This analysis reports the healthcare professional global assessment (HPGA) and patient global assessment (PGA) scores and the adverse event (AE) profile by age, body mass index (BMI), sex, and...
5.
Leiman D, Niebler G, Minkowitz H
Adv Ther . 2020 Nov; 38(1):691-706. PMID: 33237534
Introduction: Surgical site infiltration with bupivacaine HCl results in short-lived analgesia for postsurgical pain and carries the risk of systemic bupivacaine toxicity due to accidental intravascular injection. INL-001 is a...
6.
Singla N, Pollak R, Gottlieb I, Leiman D, Minkowitz H, Zimmerman J, et al.
Pain Ther . 2020 Jul; 9(2):545-562. PMID: 32683644
Introduction: This study is part of the registrational program for intravenously administered (IV) tramadol in the USA and compared the analgesic benefit and tolerability of two doses of IV tramadol...
7.
Minkowitz H, Leiman D, Lu L, Reines S, Ryan M, Harnett M, et al.
J Pain Res . 2020 Jun; 13:1155-1162. PMID: 32547178
Purpose: There is a need to reduce exposure to Schedule II opioids in the United States (US) due to the ongoing opioid epidemic. Schedule II opioids have higher potential for...
8.
Minkowitz H, Salazar H, Leiman D, Solanki D, Lu L, Reines S, et al.
Drugs R D . 2020 May; 20(3):225-236. PMID: 32409981
Background And Objective: Oral tramadol, an atypical opioid approved in the United States (US) since 1995 and a Schedule IV controlled substance, has less abuse liability compared to Schedule II...
9.
Hutchins J, Leiman D, Rafique Z, DiDonato K, Palmer P
J Perianesth Nurs . 2019 Nov; 35(1):22-28. PMID: 31732448
Purpose: To aid nurses in dosing sufentanil sublingual tablet (SST) 30 mcg administered via a single-dose applicator, dosing requirements and efficacy of SST 30 mcg were analyzed across age, sex,...
10.
Miner J, Melson T, Leiman D, Minkowitz H, Chiang Y, DiDonato K, et al.
Pain Manag . 2019 Jan; 9(3):259-271. PMID: 30614379
To evaluate the pooled safety of sufentanil sublingual tablets (SSTs) administered at 30-mcg dose equivalents over ≤72 h for moderate-to-severe acute pain management in medically supervised settings. Safety data from...